PPARG and cancer: Our findings may explain why rosiglitazone exerts anti-tumor effects in certain cancers but not others – cancers with abundant PPARγ-positive macrophages may be sensitive whereas cancers with limited macrophages or PPARγ-negative macrophages may be resistant.